Anuja Premawardhena

Prof. Anuja Premawardhena

University of Kelaniya, Kelaniya, Sri Lanka

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
RRRexan Rodrigo
Rexan Rodrigo
AAAngela Allen
Angela Allen
AMAresha Manampreri
Aresha Manampreri
LPLuxman Perera
Luxman Perera
CFChristopher A. Fisher
Christopher A. Fisher
APAnuja Premawardhena
Anuja Premawardhena

15 October 2024 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
APAnuja Premawardhena
Anuja Premawardhena
SWSakuni Wanasinghe
Sakuni Wanasinghe
CPChamodi Perera
Chamodi Perera
MWMuditha Nayana Wijethilaka
Muditha Nayana Wijethilaka
RRR.H.M.G. Rajakaruna
R.H.M.G. Rajakaruna
SMSachith Mettananda
Sachith Mettananda
Background Many patients with beta-thalassaemia die prematurely due to iron overload. In this study, we aim to evaluate the efficacy and safety of the triple combination of deferoxamine, deferasirox and deferiprone on iron chelation in patients with transfusion-dependent beta-thalassaemia with very high iron overload. Methods This open-label, randomised, controlled clinical trial was conducted at Colombo North Teaching Hospital, Sri Lanka. Transfusion-dependent beta-thalassaemia patients with ferritin >3500 ng/mL were randomised 2:1 into intervention (deferoxamine, deferasirox and deferiprone) and control (deferoxamine and deferasirox) arms. Reduction in serum ferritin after six months was the primary outcome measure. Reduction in liver iron content, improvement in cardiac T2 & lowast;, and adverse effects were secondary outcome measures. Findings Twenty-three patients (intervention-15, control-8) were recruited. 92% and 62% in the intervention and control arms showed a reduction in ferritin, respectively. The mean reduction of ferritin was significantly higher in intervention (-1094 +/- 907 ng/mL) compared to control (+82 +/- 1588 ng/mL) arm (p = 0.042). There was no statistically significant difference in the liver iron content in two arms. In the intervention arm, 67% improved cardiac T2 & lowast; (mean change +6.72 +/- 9.63 ms) compared to 20% in the control arm (mean change -3.00 +/- 8.24 ms). Five patients discontinued deferiprone due to arthralgia, which resolved completely after stopping the drug. Interpretation Triple combination therapy with deferoxamine, deferasirox and deferiprone is more efficacious in reducing iron burden measured by serum ferritin and showed a positive trend in reducing myocardial iron content in patients with transfusion-dependent beta-thalassaemia with very high iron overload. Deferiprone has the disturbing side effect of reversible but severe arthropathy. Copyright (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

19 October 2022 in Thalassemia Reports
Verified
Journal Article
Open access
PDF file
NANadeeja Indu Amarasinghe
Nadeeja Indu Amarasinghe
AAAmila Erandi Amarasena
Amila Erandi Amarasena
Wijayawarnakula Indika Anoj ThabrewWijayawarnakula Indika Anoj Thabrew
Wijayawarnakula Indika Anoj Thabrew
PWPrabhath Werawatte
Prabhath Werawatte
APAnuja Premawardhena
Anuja Premawardhena
SWShiranee Champika Wickramasinghe
Shiranee Champika Wickramasinghe
Sri Lanka, a country with 22 million people, has nearly 2000 thalassemia patients with severe thalassemia, two-thirds of whom have beta thalassemia major (TM). The current prevention program based on promoting “safe marriages”, which has been in existence for over 15 years, has failed to reduce thalassemia major births. We set about to examine the cost-effectiveness of novel policy options for thalassemia prevention in Sri Lanka. Methods: The current cost for treatment of a thalassemia major patient (USD 2602/yr) was compared against the cost per reduction of single birth with three novel strategies, namely intensifying the screening in the current five districts combined with an education program (policy option 1), a nationwide screening program (policy option 2), and antenatal screening combined with the termination of pregnancy (policy option 3). The incremental cost-effectiveness ratio (ICER) of the different strategies was calculated. Results: The status quo was considered to reduce one TM birth whilst the new policy options were able to reduce births by 14, 35, and 48, respectively. The costs incurred for the program for a year for status quo and the three novel programs were USD 104,788, 173,884, 781,372, and 904,186 respectively. Cost per prevention of a thalassemia major birth was USD 87,324, 12,420, 22,324, and 20,084, respectively. The lifetime cost per treatment of a thalassemia major patient was USD 34,653. Conclusions: Given the current legal restriction on termination of pregnancy for fetal indications, policy option 2, an island-wide screening with mass education, is the most cost-effective and will be expected to deliver a substantial reduction in new births.

2 January 2022 in Hemoglobin
Verified
Journal Article
Closed access
APAnuja Premawardhena
Anuja Premawardhena
HMH. D. Prabath Madushanka
H. D. Prabath Madushanka
The island nation of Sri Lanka with 22 million people (in 2020) has an estimated 2000 patients with severe thalassemia. The majority have β-thalassemia (β-thal) major (β-TM), and Hb E (HBB: c.79G>A)/β-thal accounts for most of the remainder. Carrier rate for α+-thalassemia (α+-thal) trait is 9.9% and β-thal trait is 2.5%, with very similar rates in the three major ethnic groups (Sinhalese, Tamils and Moors). The distribution of thalassemia type reveals a remarkable variation, even in this small island, mirroring historical distribution of malaria. Even though healthcare is provided free by the state including blood transfusions and chelation, the overall survival of patients of β-TM is still not on a par with that of the Mediterranean countries. A national thalassemia prevention program was set up in 2007, but overall success of the exercise based essentially on dissuasion of marriages is not very promising.

9 March 2023 in International Journal of Emergency Medicine
Verified
Journal Article
Open access
PDF file
APAnuja Premawardhena
Anuja Premawardhena
SSShamila De Silva
Shamila De Silva
MRMegha Rajapaksha
Megha Rajapaksha
VRVishaka Ratnamalala
Vishaka Ratnamalala
JNJemimah Nallarajah
Jemimah Nallarajah
GGGamini Galappatthy
Gamini Galappatthy
Background: Cardiac disease remains a dominant if not the most important cause of morbidity and mortality in patients with thalassaemia, particularly in those with thalassaemia major. Myocardial infarction and coronary artery disease however are rarely reported. Case presentations: Three older patients with three distinct thalassaemia syndromes presented with acute coronary syndrome. Two were heavily transfused whilst the other was a minimally transfused patient. Both heavily transfused patients had ST-elevation myocardial infarctions (STEMI) while the minimally transfused patient had unstable angina. Coronary angiogram (CA) was normal in two patients. One patient who developed a STEMI had a 50% plaque. All three were managed as standard ACS, although the aetiology appeared non-atherogenic. Conclusions: The exact etiology of the presentation, remains a mystery and therefore the rational use of thrombolytic therapy, carrying out angiogram in the primary setting, using and continuing antiplatelet and high dose statins all remains unclear in this sub group of patients.

15 January 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
NFNilshan Fernando
Nilshan Fernando
KFKavindya Fernando
Kavindya Fernando
SWSenani Williams
Senani Williams
APAnuja Premawardhena
Anuja Premawardhena
Introduction Acalypha indica (AI) is an Ayurvedic medicinal plant. Some of this plant’s phytochemicals have been reported to cause oxidative stress in red blood cells. However, we know very little about those chemicals due to a dearth of literature. We present a case in which a patient with a previously unidentified glucose-6-phosphate dehydrogenase (G6PD) deficiency experienced acute hemolysis after ingesting fresh AI plant leaves. Case Presentation A 65-year-old man presented with jaundice, pallor, and haematuria following ingestion of the "Kuppamenia mallum" dish. His peripheral blood picture showed bite cells and Heinz bodies. A positive Brewer's test raised the clinical suspicion of G6PD deficiency. Low values of the G6PD level assessment at the follow-up visit confirmed the diagnosis. Conclusion Although AI is regarded as a medicinal plant, acute hemolysis can also occur after consumption in G6PD-deficient patients. This case emphasises the need for further research to identify the phytochemicals and their concentrations that can induce toxicity.